Research Analysts Offer Predictions for Repligen Q1 Earnings

Repligen Corporation (NASDAQ:RGEN) – Equities research analysts at Leerink Partnrs boosted their Q1 2026 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Tuesday, October 28th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will post earnings of $0.48 per share for the quarter, up from their previous forecast of $0.47. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q3 2026 earnings at $0.54 EPS, Q4 2026 earnings at $0.65 EPS and FY2026 earnings at $2.19 EPS.

RGEN has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Repligen in a research note on Wednesday, October 8th. Wells Fargo & Company dropped their price objective on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 30th. Canaccord Genuity Group boosted their price objective on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday. Royal Bank Of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Finally, Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.85.

Repligen Stock Up 3.1%

Shares of Repligen stock opened at $149.06 on Friday. The business’s fifty day moving average price is $135.41 and its two-hundred day moving average price is $128.91. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The company has a market capitalization of $8.39 billion, a P/E ratio of 7,456.73, a PEG ratio of 3.32 and a beta of 1.08. Repligen has a 1-year low of $102.96 and a 1-year high of $182.52.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. The firm had revenue of $188.80 million for the quarter, compared to the consensus estimate of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The firm’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS.

Insider Activity

In related news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Repligen

Hedge funds have recently modified their holdings of the stock. Twin Tree Management LP acquired a new position in shares of Repligen in the 1st quarter worth $29,000. Hantz Financial Services Inc. grew its holdings in shares of Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 128 shares during the last quarter. CWM LLC grew its holdings in shares of Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 135 shares in the last quarter. Finally, Center for Financial Planning Inc. grew its holdings in shares of Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 126 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.